Table 2.
Correlation of lnc-MALAT1/miR-125b with FOXQ1, PTGS2 or CDK5
| Items | Genes | MiR-125b | FOXQ1 | PTGS2 | CDK5 | ||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
||||||
| P value | r | P value | r | P value | r | P value | r | ||
| AD patients | |||||||||
| CSF samples (N = 50) | Lnc-MALAT1 | < 0.001 | -0.513 | 0.024 | 0.320 | < 0.001 | -0.525 | 0.042 | -0.289 |
| MiR-125b | - | - | 0.001 | -0.470 | 0.001 | 0.472 | 0.001 | 0.473 | |
| Plasma samples (N = 120) | Lnc-MALAT1 | < 0.001 | -0.367 | < 0.001 | 0.451 | 0.002 | -0.282 | 0.099 | -0.151 |
| MiR-125b | - | - | < 0.001 | -0.340 | 0.001 | 0.307 | 0.026 | 0.203 | |
| PD patients | |||||||||
| CSF samples (N = 50) | Lnc-MALAT1 | 0.003 | -0.416 | 0.183 | 0.191 | 0.001 | -0.446 | 0.112 | -0.228 |
| MiR-125b | - | - | 0.425 | -0.115 | < 0.001 | 0.529 | 0.155 | 0.204 | |
| Plasma samples (N = 120) | Lnc-MALAT1 | < 0.001 | -0.358 | 0.205 | 0.116 | 0.558 | -0.054 | 0.773 | -0.027 |
| MiR-125b | - | - | 0.120 | -0.143 | 0.100 | 0.151 | 0.002 | 0.283 | |
| Ctrls | |||||||||
| CSF samples (N = 50) | Lnc-MALAT1 | 0.003 | -0.408 | 0.020 | 0.328 | 0.020 | -0.328 | 0.056 | -0.272 |
| MiR-125b | - | - | 0.016 | -0.339 | 0.109 | 0.229 | 0.019 | 0.330 | |
| Plasma samples (N = 120) | Lnc-MALAT1 | 0.006 | -0.249 | 0.058 | 0.173 | 0.013 | -0.225 | 0.085 | -0.158 |
| MiR-125b | - | - | 0.002 | -0.284 | 0.681 | 0.038 | 0.076 | 0.163 | |
Correlation was determined by Spearman’s rank correlation test. FOXQ1, forkhead box Q1; PTGS2, prostaglandin-endoperoxide synthase 2; CDK5, cyclin dependent kinase 5; Ctrls, controls; AD, Alzheimer’s disease; CSF, cerebrospinal fluid; Lnc-MALAT1, long noncoding RNA metastasis-associated lung adenocarcinoma transcript 1; miR-125b, microRNA 125b; PD, Parkinson’s disease.